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Abstract
Background: Pelvic lymph nodes metastasis is an important prognostic factor for patients with
cervical carcinoma. However, the relationships between the number of positive nodes, site of
metastases nodes, adjuvant therapy and the prognosis is controversial. The purpose of this study
was to investigate the influence of positive lymph nodes on the prognosis of Chinese women with
stage IB1-IIB cervical carcinoma.
Patients and methods: Between January 1992 and December 1997, 398 women with
International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIB cervical carcinoma
underwent radical surgery in Cancer Hospital, Fudan University. Of these sixty-six patients (16.6%)
who were histologically confirmed to have positive pelvic lymph nodes were analyzed
retrospectively. The survival was estimated using Kaplan-Meier method. The differences in survival
were compared with Log-rank test. Multivariate analyses were performed with the Cox
proportional hazard model.
Results: The 5-year survival of the patients with pelvic lymph nodes metastases was 40.7%. Cox
proportional hazard model analysis showed that cellular differentiation, the number of positive
nodes and adjuvant therapy to be the independent prognostic factors (P < 0.05). The 5-year survival
of patients with one positive node was higher than that of those with two or more positive nodes
(56.5% vs. 36.4%, P < 0.05). The distant metastasis rate in the former group (5.9%) was lower than
the latter's (32.7%) (P = 0.05). However, there was no significant difference of pelvic recurrence
between the two groups (P > 0.05). The number of positive nodes positively correlated with the
level of positive nodes (P < 0.01). The 5-year survival of the patients who had no adjuvant therapy
(12.6%) was much lower than that (53.7%) of those with adjuvant therapy (P < 0.05). However,
there was no obvious difference between adjuvant radiotherapy, chemotherapy and chemo-
radiotherapy (P > 0.05).
Conclusions: The prognosis of patients with stage IB1-IIB node-positive cervical carcinoma who
underwent radical surgery alone was very poor. Adjuvant therapy increases the survival rate,
decreases the pelvic recurrence and distant metastasis.
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Background
Although radical radiotherapy (RT) and radical surgery
can be the proper choices for patients with early stage cer-
vical cancer, most of the patients in China prefer the radi-
cal surgery to RT. Hence, in China the radical surgery has
been widely used as first-line therapy for this group of
women. Some poor prognostic subgroups have been
identified, among these the pelvic lymph node status has
been considered as the most important prognostic factor.
Radical hysterectomy with bilateral pelvic lymphadenec-
tomy produces an expected 85–90% survival in women
with stage IB and IIA cervical carcinoma without lym-
phatic spread. However, once tumors involve regional
lymph nodes, 5-year survival has been reported to be only
30–60% [1]. In most of the studies the presence of pelvic
lymph node metastases has been associated with
increased pelvic recurrence and distance metastases, and a
decrease in overall survival [2-7]. However, many ques-
tions such as the relationship between the numbers, the
site of positive nodes, the modality of postoperative
multidisciplinary therapy and the prognosis is not yet
clear. This study investigated the factors that could predict
the prognosis of the patients with stage IB1-IIB node-pos-
itive cervical carcinoma.
Patients and methods
Between January 1992 and December 1997, 398 women
with International Federation of Gynecology and Obstet-
rics (FIGO) stage IB1-IIB cervical carcinoma underwent
radical surgery at the Department of Gynecologic Oncol-
ogy, Cancer Hospital of Fudan University. Of these 66
patients who had undergone Wertheims-Meigs' surgery
(radical hysterectomy and pelvic lymphadenectomy) and
were histologically confirmed to harbor positive pelvic
lymph node were included in this study. The median age
at diagnosis was 49 years (range 21 to71). Out of 66, 8
patients were in stage IB1 (12.1%), 37 patients (56.1%) in
stage IIA and 21 patients (31.8%) in stage IIB. Histologi-
cally 41 women (62.1%) had squamous carcinoma, 20
(30.3%) had adenocarcinoma, 4 (6.1%) adenosquamous
carcinoma and 1 patient (1.5%) had small cell carcinoma.
The tumors in 4 patients (6.1%) were well differentiation,
46 cases (69.7%) moderately differentiated and 16
(24.2%) poorly differentiated. The average lymph nodes
resected were 14.8 per patient while the average positive
lymph nodes resected were 3.7 (1~28) per patient. The
average diameter of the cervical tumors was 3.6 cm (1~7
cm). The details of the patients' clinical characteristics are
listed in Table 1.
Sixty four of these women (97.0%) had brachytherapy in
either three or four fractions with a total dose of 15~20 Gy
at point A, two weeks prior to radical surgery because of
bulky tumor or vaginal vault involvement. Intra-arterial
chemotherapy was administered to 11 patients (16.7%)
before surgery because of bulky tumor or parametrial
extension. The regimen based on cisplatin (CDDP) + 5-
Fluorouracil(5-FU) with 2~3 cycles at 3-weeks intervals
was used. All patients underwent Wertheims-Meigs' pro-
cedure that included radical hysterectomy and bilateral
pelvic lymphadenectomy. Three patients had para-aortic
lymph node (PALN) sampling because there was suspi-
cion of metastasis.
Postoperative external beam irradiation was delivered to
18 patients (27.3%) with 6 MV X-ray routine anterior and
posterior portal at a dose of 35~45 Gy at point B with 1.8
Gy daily fraction. Two patients with positive vaginal mar-
gin were given extra brachytherapy with 15 Gy 0.5 cm
below the vaginal mucosa. 12 cases with positive com-
mon iliac node and 3 with PALN metastasis received an
additional 40 Gy to the PALN chain area. 10 patients
Table 1: Clinico-pathologic characteristics of patients with node-
positive cervical carcinoma after radical surgery
Factors n Percentage (%)
Age(yrs)
<40 15 22.7
≥40 51 77.3
Stage
IB 8 12.1
IIA 37 56.1
IIB 21 31.8
Tumor size(cm)
<4 31 47.0
≥43 5 5 3 . 0
Histology
Squamous 41 62.1
Adenocarcinoma 20 30.3
Adenosquamous 4 6.1
Others 1 1.5
Differentiation
Poor 16 24.2
Moderate 46 69.7
Well 4 6.1
Pelvic lymph node metastases
11 7 2 5 . 8
≥24 9 7 4 . 2
Parametrial extension
Negative 58 87.9
Positive 8 12.1
Vaginal margin involved
Negative 64 97.0
Positive 2 3.0
Depth of stromal invasion
≤2/3 19 28.8
≤2/3 47 71.2
Lymphvascular permeation
Negative 47 71.2
Positive 19 28.8World Journal of Surgical Oncology 2004, 2:47 http://www.wjso.com/content/2/1/47
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(15.2%) were given postoperative chemotherapy. The reg-
imen consisted CDDP + 5-FU + Cyclophosphamide
(CTX) for squamous carcinoma, and CDDP + 5-FU +
Mitomycin (MMC) for adenocarcinoma with 2~6 cycles at
3~4-weeks intervals. A total of 19 patients (28.8%)
received adjuvant radiotherapy and chemotherapy as
mentioned above.
Follow-up
Patients were evaluated every two months for the first two
years and then six monthly for the additional years by
clinical interview, or telephone, or letters. Disease-free
survival (DFS) was defined as the time from the date of
surgery to local or nodal recurrence or metastasis. Overall
survival (OS) was calculated from the date of surgery to
the date of death. Recurrences were defined as local if they
were detected in the pelvis or vagina and distant metas-
tases as detected in extra-pelvic locations. The median fol-
low-up time was 32 months (range 2~108 months).
Statistical analysis
Data analysis was performed with Statistical package for
social sciences (SPSS) version 10.0 statistical package. The
survival was calculated by Kaplan-Meier method. The dif-
ferences in survival were compared with Log-rank test.
Multivariate analyses were performed with the Cox pro-
portional hazard model. The correlation analysis was per-
formed by Kendall's method. Pearson's chi-square or
Fisher's exact test was used to compare the difference of
proportions. A probability value of P < 0.05 was consid-
ered significant.
Results
The 5-year overall survival of the patients with pelvic
lymph node metastasis was 40.7%. The 5-year survival of
patients with one positive node (56.5%) was higher than
that (36.4%) of those with two or more positive nodes (P
< 0.05). The former's distant metastasis rate (5.9%) was
lower than the latter's (32.7%) (P = 0.05). However, there
was no significant difference of pelvic recurrence between
them (P > 0.05) (Table 2, Figure 1)
The 5-year survival (33.3%) of the patients with positive
common iliac node and paraaortic lymph node (PALN)
was less than that (43.1%) of   patients with lower than
common iliac node involvement. However, the difference
was not significant (P > 0.05). The former's pelvic recur-
rence rate (13.3%) was lower than the latter's (29.4%) (P
> 0.05). However, the patients with common iliac or
paraaortic nodes had significantly higher distant metasta-
sis (53.3%) than that of the patients with lower nodes
(17.6%) (P < 0.01). The number of the positive lymph
nodes was closely correlated with the level of lymph node
metastasis. The relative coefficient was 0.557 (P < 0.01)
(Table 3).
The 5-year survival (12.6%) of the   patients who had no
adjuvant therapy was much lower than that (53.7%) of
those with adjuvant therapy (P<0.05). The 5-year survival
rates of the adjuvant radiotherapy, adjuvant chemother-
apy, and adjuvant radio-chemotherapy groups were
53.5%, 49.2% and 56.1% respectively (P > 0.05). The pel-
vic recurrence (42.1%) and distant metastasis (31.6%) of
the surgery alone were higher than those with adjuvant
therapeutic groups. However, the differences were not sig-
nificant (P > 0.05) (Table 4, Figure 2)
Multivariate analysis of prognostic factors
Cox proportional hazard model analysis showed that cel-
lular differentiation, number of positive nodes and adju-
vant therapy to be the independent prognostic factors for
survival (P < 0.05) (Table 5)
Discussion
Cervical cancer remains the third common cancer in
women around the world, although its incidence is on the
decline in North American and in Europe. It is estimated
that there will be 10,370 new cases in 2005 in North
America [8]. In many developing countries, not only is
cervical cancer the most frequently occurring cancer
among middle-aged women, but it is also a leading cause
of death, partly due to the poor access to medical care and
the unavailability of routine screening in many of these
countries [9]. In Shanghai, the biggest city in China, there
were 150 new cases in 2000. The standard incidence rate
was 2.9 per 100 000 [10].
Radical surgery has been found to be very effective in
patients with early stage (IB-IIA) cervical carcinoma [11-
13]. However, the 5-year survival has been lingering at
Table 2: Relationship between the number of positive nodes and prognosis
Number of 
positive nodes
n5 - y e a r  s u r v i v a l  
(%)
P Recurrence rate 
(%)
P Metastasis rate 
(%)
P
1 17 56.5 0.033 23.5 0.807 5.9 0.050
≥2 49 36.4 26.5 32.7World Journal of Surgical Oncology 2004, 2:47 http://www.wjso.com/content/2/1/47
Page 4 of 8
(page number not for citation purposes)
50%-90% during the past twenty years [14]. The reported
risk factors of cervical carcinoma included clinical stage,
bulky tumor, histological types, cellular differentiation,
deep stromal invasion, parametrial extension, vaginal
margin involved, lymphvascular permeation, lymph node
metastasis, race and age [13,15-18]. In most studies the
presence of pelvic lymph node metastases has been asso-
ciated with increased pelvic recurrence and distance
metastases, and a decrease in overall survival. Our Cox
proportional hazard model analysis showed cellular dif-
ferentiation, number of positive nodes and adjuvant ther-
apy to be the independent prognostic factors (P < 0.05).
The 5-year survival of patients with one positive node
(56.5%) was higher than that (36.4%) of those with two
Overall survival according to one vs. two or more positive lymph nodes Figure 1
Overall survival according to one vs. two or more positive lymph nodes.
Table 3: Relationship between the site of positive nodes and prognosis
Site n 5-year survival rate 
(%)
P Recurrence rate 
(%)
P Metastasis rate 
(%)
P
Common iliac or above 15 33.3 0.086 13.3 0.318 53.3 0.005
Lower than common iliac 51 43.1 29.4 17.6World Journal of Surgical Oncology 2004, 2:47 http://www.wjso.com/content/2/1/47
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Table 4: Relationship between adjuvant therapy and prognosis
n 5-year survival (%) Recurrence rate (%) Metastasis rate (%)
No adjuvant therapy 19 12.6 42.1 31.6
Radiotherapy 18 53.5 22.2 22.2
Chemotherapy 10 49.2 20.0 10.0
Radiochemotherapy 19 56.1 15.8 21.1
Overall survival according to adjuvant therapy [radiotherapy (RT) vs. chemotherapy (CT) vs. radiochemotherapy (RT+CT) vs.  no adjuvant therapy (No)] Figure 2
Overall survival according to adjuvant therapy [radiotherapy (RT) vs. chemotherapy (CT) vs. radiochemotherapy (RT+CT) vs. 
no adjuvant therapy (No)].World Journal of Surgical Oncology 2004, 2:47 http://www.wjso.com/content/2/1/47
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or more positive nodes (P  < 0.05). There was no
significant difference of pelvic recurrence between them.
However, the former's distant metastases rate (5.9%) was
lower than the latter's (32.7%) (P = 0.05). In the analysis
of the site of lymph node metastases, the 5-year survival
(33.3%) of the patients with positive common iliac node
and paraaortic lymph node (PALN) was lower than that
(43.1%) of patients with lower than common iliac node
involvement. Unlike the series of Tsai the difference in our
series was not statistically significant [19]. This is probably
due to limited number of cases with paraaortic or com-
mon iliac nodes. The number of positive nodes correlated
with the height of positive nodes (P < 0.01). The result
suggested that in patients with more positive pelvic nodes
there is higher chance of nodal metastasis at higher level
node basins, which supported the external irradiation of
PALN chain area for the multiple pelvic nodes involve-
ment. The distant metastasis rate was 32.7% in patients
with multiple positive lymph nodes, which showed the
limitation of adjuvant radiotherapy and theoretically sup-
ported the postoperative combined chemotherapy.
The prognosis of patients with positive lymph node was
poor because of local recurrence and distant metastasis.
How to improve the prognosis of these patients has been
the focus of gynecological oncology. Stock et al [7] com-
pared postoperative whole pelvic irradiation with those
treated with radical hysterectomy alone, and showed a sig-
nificantly improved pelvic control rate, 5-year disease-free
survival (DFS) and overall survival (OS) (78% Vs 45%,
65% Vs 41%, 58% Vs 46%, respectively).
Peters' study [20] demonstrated that postoperative radio-
chemotherapy could greatly improve the 4-year DFS and
OS compared to the adjuvant radiotherapy alone. In our
study, adjuvant therapy improved the 5-year survival than
the surgery alone (53.7% vs. 12.6%), decreased the pelvic
recurrence and distant metastasis, which suggested the
clinical importance of adjuvant therapy in patients with
positive nodes. In this study the 5-year survival of adju-
vant radio-chemotherapy arm was higher than adjuvant
radiotherapy alone or chemotherapy alone. The pelvic
recurrence (42.1%) and distant metastasis (31.6%) of the
surgery alone were higher than the other three therapeutic
arms. However, the differences were not significant and
the limited number of cases in each arm could be the rea-
son. It is necessary that these results are verified in pro-
spective randomized control trials.
Several randomized clinical trials [20-25] performed by
the Gynecologic Oncology Group (GOG), the Radiation
Therapy Oncology Group (RTOG) and the Southwest
Oncology Group (SWOG) have demonstrated a signifi-
cant advantage both in DFS and OS when cisplatin-based
chemotherapy was administered during radiation for
advanced stages of cervical cancer and early stage disease
with poor prognostic factors. Green et al [26] did a sys-
temic review of all known randomized controlled trials
published between 1981 and 2000, 2865–3611 patients
were available for analysis. The findings suggested that
concomitant chemotherapy (CT) and radiotherapy (RT)
improves OS and DFS, and reduces local and distant
recurrence. Based on results, the US National Cancer Insti-
tute (NCI) released a clinical announcement supporting
the concurrent use of cisplatin-based chemotherapy with
RT for high-risk early stage and locally advanced stage cer-
vical cancer [9,27]. Recently a prospective randomized
trial performed by the National Cancer Institute (NCI) of
Canada [25] failed to show benefit with the use of chem-
oradiation compared with RT alone. The potential inclu-
sion of paraaortic nodes positive patients and the
Table 5: Cox proportional hazard model analysis of variables in predicting overall survival
Factors Coefficient RR 95%CI P
Age -0.031 0.970 0.932~1.010 0.136
Stage 0.283 1.327 0.379~4.644 0.658
Tumor size 0.332 1.394 0.984~1.975 0.061
Histology -0.035 0.966 0.563~1.659 0.900
Differentiation 0.787 2.196 1.104~4.370 0.025*
Number of positive nodes 0.076 1.079 1.006~1.158 0.034*
Parametrial extension 0.484 1.623 0.584~4.508 0.353
Vaginal margin involved -1.007 0.365 0.029~4.655 0.438
Depth of stromal invasion 0.423 1.526 0.856~2.722 0.152
Lymphvascular permeation 0.270 1.311 0.500~3.437 0.582
Nerve invasion 0.101 1.106 0.092~13.337 0.937
Adjuvant therapy -1.684 0.186 0.075~0.459 0.000*
* P < 0.05World Journal of Surgical Oncology 2004, 2:47 http://www.wjso.com/content/2/1/47
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significant difference in anemia raises question about this
trial result [28].
The therapy of patients with stage IIB cervical carcinoma
is still a controversy [29]. Although radical radiotherapy
(RT) is the proper choice for patients with stage IIB cervi-
cal cancer in general, the therapeutic effect is not as good
as expected if the tumor is too bulky or is histologically
adenocarcinoma. Hence a few gynecology oncologists
tried brachytherapy and/or neoadjuvant chemotherapy to
decrease the lesion, then performed radical surgery for
some stage IIB patients with bulky tumor (>4 cm) or slight
(less than 1/2) parametrial extension [30,31]. Postopera-
tive adjuvant therapy would then be recommended
according to risk factors [9,17,20,32]. In our study, the 5-
year survival of the patients with stage IIB cervical carci-
noma was only 54.3%, which was not at all satisfactory
compared with the reported 58.9%–80.1% [33-35]. So we
advocate that radical surgery should be taken cautiously
for this group of patients. Any attempt to improve their
prognosis by means of adjuvant therapy is not
recommended if the parametrium can not be thoroughly
dissected from the pelvic wall.
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